Federal support for psychedelic research expands as HPL-003 advances as an intranasal psilocin candidate for depression treatment and clinical development

Federal support for psychedelic research is expanding while HPL-003 is moving forward as a depression treatment candidate based on intranasal psilocin delivery. Depression remains a major clinical target for psychedelic drug development, and policy signals from US agencies are shaping how quickly trials and commercialization can progress. HPL-003 is positioned within a broader pipeline of psychiatric therapies seeking faster onset, more controllable dosing, and scalable clinical use. Intranasal administration may offer practical advantages over longer, less predictable treatment formats, especially for patients and clinics that need standardized delivery and clearer safety management. Government backing matters because funding, regulatory engagement, and institutional legitimacy can accelerate study design, recruitment, and eventual approval pathways. Psychedelic medicine is increasingly shifting from fringe status toward mainstream psychiatric research, with depression at the center of that transition.